Explore our easy plasmid services starting at just $249. Our fully sequenced plasmids, ready for your research, include a miniprep. Reduce project cos...
Ready to use, synthetic and free of any animal-origin component
Lentiviral vectors (LV) manufacturing using HEK-293 derivative cells cultivated in suspension
|Number of transfections|
100 mL of FectoVIR®-LV transfection reagent is sufficient to transfect on average 50 L of cell culture (using standard conditions)
Store FectoVIR®-LV at 5 °C ± 3°C.
Lentiviral vectors are recognized to be the carrier of choice for allogenic or autologous cell therapies (such as CAR-T) because of its capacity to permanently integrate viral genome into host cell DNA. To produce those vectors, cell therapy producers generally use a transient transfection system that is scaled-up during process development phases. FectoVIR®-LV is the next generation of transfection reagent, free of animal component, designed to improve LV productivity in HEK-293 cell systems. FectoVIR®-LV is made for large scale manufacturing with reduction of the complexation volume and increased complex stability. The FectoVIR®-LV benefits allow to increase number of doses produced per batch to treat more patient, while decreasing LV manufacturing costs.
Discover Polyplus’ complementary DOE service to fast-track optimization of lentivirus production with FectoVIR®-LV.
Improve lentiviral vector productivity using FectoVIR®-LV
The production of lentiviral vectors for cell and gene therapy is performed using 3rd generation plasmid systems in HEK-293 and derivative cell systems. Transfection reagents are considered as a critical raw material because of its major impact on productivity. Choosing the transfection reagent based on the best titers is a must for process economics and intensification. FectoVIR®-LV increases up to 3-fold functional titers in comparison to other commercially available lentivirus-specific transfection reagents.
Reduce lentiviral vector manufacturing costs using DOE approach
Improving titers is one of the key parameters to increase number of doses per batch and reduce cost per dose. When combined with reduced .consumption of additional critical raw material such as DNA quantity, overall manufacturing costs can be further reduced. FectoVIR®-LV both allows gain in productivity while reducing by 2-fold DNA consumption. To support our customers, Polyplus offers a comprehensive DOE service to optimize key parameters of transfection step to reach higher titers.
Increase your scale without being limited by the transfection mix
Transient transfection at large scale comes with challenges, of which transfer of transfection mix within an optimal trimeframe. This step can be a limit if the transfection reagent is not adapted for large scale manufacturing. FectoVIR®-LV has been designed to increase complex stability and decrease complex volume allowing sufficient time to transfer the mix into large bioreactors (>200 L). FectoVIR®-LV has proven its efficiency using the recommended 5% complexation volume and 30 min of complexation volume, which can be even further optimized to fit your process. Polyplus recommends performing a DOE study adapted to your system.
We power your process with fast process optimization
Manufacturing lentiviral vectors for therapeutic treatments (ex. vivo gene therapy and cell therapy) requires the right set of tools.
Find the Information you need
Get in depth coverage on how to accelerate your process optimization : Link to DOE page
Check our FAQs
These FAQs are organized by application to guide you to find the best answer possible.
You have access to all the documents related to the transfection reagent.
Search for publications in our Transfection Database with Polyplus transfection reagents
This lexicon will help you to understand the different terms related to Polyplus-transfection®.